- Home
- MPA vs RCEL Comparison
MPA vs RCEL Comparison
Compare MPA & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPA
- RCEL
- Stock Information
- Founded
- MPA 1992
- RCEL N/A
- Country
- MPA United States
- RCEL United States
- Employees
- MPA N/A
- RCEL N/A
- Industry
- MPA Finance Companies
- RCEL Medical/Dental Instruments
- Sector
- MPA Finance
- RCEL Health Care
- Exchange
- MPA Nasdaq
- RCEL Nasdaq
- Market Cap
- MPA 139.5M
- RCEL 158.1M
- IPO Year
- MPA N/A
- RCEL N/A
- Fundamental
- Price
- MPA $10.76
- RCEL $5.63
- Analyst Decision
- MPA
- RCEL Strong Buy
- Analyst Count
- MPA 0
- RCEL 4
- Target Price
- MPA N/A
- RCEL $14.75
- AVG Volume (30 Days)
- MPA 25.2K
- RCEL 423.6K
- Earning Date
- MPA 01-01-0001
- RCEL 08-07-2025
- Dividend Yield
- MPA 3.83%
- RCEL N/A
- EPS Growth
- MPA N/A
- RCEL N/A
- EPS
- MPA N/A
- RCEL N/A
- Revenue
- MPA N/A
- RCEL $74,884,000.00
- Revenue This Year
- MPA N/A
- RCEL $57.16
- Revenue Next Year
- MPA N/A
- RCEL $36.69
- P/E Ratio
- MPA N/A
- RCEL N/A
- Revenue Growth
- MPA N/A
- RCEL 38.32
- 52 Week Low
- MPA $9.87
- RCEL $3.60
- 52 Week High
- MPA $12.21
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- MPA 52.25
- RCEL 52.24
- Support Level
- MPA $10.75
- RCEL $5.53
- Resistance Level
- MPA $10.92
- RCEL $6.00
- Average True Range (ATR)
- MPA 0.08
- RCEL 0.41
- MACD
- MPA 0.01
- RCEL 0.06
- Stochastic Oscillator
- MPA 57.87
- RCEL 79.61
About MPA Blackrock MuniYield Pennsylvania Quality Fund
Blackrock Muniyield Pennsylvania Quality Fund is a closed-end fund with investment objective is to provide shareholders with as high a level of current income exempt from U.S. federal and Pennsylvania income taxes as is consistent with its investment policies and prudent investment management.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.